Newsletter
The life sciences briefing that 42,000 professionals start their day with.
Sharp, essential coverage of clinical trials, biopharma, regulatory policy, and innovation, delivered straight to your inbox.
A sweeping meta-analysis of two decades of clinical data asks whether the precision medicine premium has permanently compressed, and what that means for portfolio construction heading into the second half of 2026.
The FDA's updated clinical trial transparency requirements are now in effect. Regulatory and legal teams walk through the six areas most likely to require new data infrastructure, revised submissions, and external audit support.
New research maps the capabilities separating the CSOs who are driving strategic transformation from those still managing pipelines, and the specific behaviours that define the difference.
Life Sciences Weekly Research
State of Life Sciences R&D Report
of CSOs say AI has already changed at least one core R&D process in their organisation, up from 31% the prior year.
HealthTech Benchmark
Digital Health Adoption Survey
Projected annual cost savings from AI-powered clinical trial optimisation across companies with pipeline assets above Phase II.
Deal Intelligence Report
Biotech M&A Pulse
Median time-to-term-sheet for sub-$500M biotech acquisitions has compressed by 9 days year-on-year as digital diligence tools reach mainstream adoption.
